In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

Thomas Karagiannis; Ioannis Avgerinos; Apostolos Tsapas

doi:10.7326/annals-26-00991-jc

May 4, 2026Annals of Internal Medicine

In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

View at Publisher

Ask AI

Bookmark

Share

Key Points

To compare the cardiovascular outcomes of tirzepatide and dulaglutide in adults with T2D and ASCVD.
Randomized trial
Evaluated tirzepatide and dulaglutide in adults with T2D and ASCVD
Follow-up period of 4 years
Tirzepatide was noninferior to dulaglutide for composite CV outcomes
Study had a median follow-up duration of 4 years

Implication

Trial shows comparable composite cardiovascular outcomes in adults treated with tirzepatide versus dulaglutide, suggesting effective management strategies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Karagiannis et al. (2026) studied this question.

synapsesocial.com/papers/69fbef86164b5133a91a35fa https://doi.org/10.7326/annals-26-00991-jc

View at Publisher

Ask AI

Bookmark

Share

In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

Key Points

Implication

Abstract

Discussion

Cite This Study

In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading